ArticleNeuro-oncology2008
The utility of body FDG PET in staging primary central nervous system lymphoma.
Article in Neuro-oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04516655 (A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma
Who cites it
46 citing papers in PubMed, 140 citations in OpenAlex.
- [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.Radiation oncology (London, England) · 2008Trial
- Prognostic Impact of Clinical Diagnosis-based Treatment in Glioblastoma Patients Aged ≥80 Years: A Single-center Cohort Study Focused on Performance Status Maintenance.Neurologia medico-chirurgica · 2026Article
- Primary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report.Cureus · 2026Article
- Molecular Analysis of Liquid Vitreous Biopsy Reveals Occult Lymphoma Following Cytology-Negative Biopsies of the Brain and Vitreous.Ocular immunology and inflammation · 2024Article
- Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature.Brain tumor pathology · 2024Review
- Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta neurochirurgica · 2024Review
- Primary central nervous system lymphoma.Journal of neurology · 2024Review
- Extranodal lymphoma: pathogenesis, diagnosis and treatment.Molecular biomedicine · 2023Review
- Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.Annals of hematology · 2023Article
- Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.Annals of hematology · 2023Article
- Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL.Neurologia medico-chirurgica · 2023Article
- Review
- Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma.Neuro-oncology · 2022Article
- An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.Frontiers in oncology · 2022Review
- Primary central nervous system lymphoma: advances in MRI and PET imaging.Annals of lymphoma · 2021Article
- Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).Neuro-oncology · 2021Article
- Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of CombiningNeurologia medico-chirurgica · 2021Article
- Relapsed Primary Central Nervous System Lymphoma: Current Advances.Frontiers in oncology · 2021Review
- Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.Journal of neuro-oncology · 2020Article
- Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.CNS oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established. We investigated the ability of body FDG PET to detect systemic disease in the staging and restaging of PCNSL. The records of 166 PCNSL patients seen at Memorial Sloan-Kettering Cancer Center were examined. Forty-nine patients who underwent body FDG PET for staging of PCNSL were identified. Clinical data were reviewed to determine FDG PET results and their influence on therapy. Body FDG PET disclosed a systemic site of malignancy in 15% of patients. NHL was found in 11% of all patients, 7% of patients at diagnosis, and 27% of patients at CNS relapse. Four percent had a second systemic neoplasm. Workup with conventional staging did not reveal systemic disease, and in 8% of patients, body FDG PET was the only abnormal diagnostic exam suggestive of lymphoma. FDG PET findings altered patient treatment and resulted in additional chemotherapy, surgery, or radiotherapy. Our findings suggest that FDG PET may be more sensitive than conventional body staging and may disclose higher rates of concomitant systemic disease at PCNSL diagnosis. Body FDG PET may be an important noninvasive adjunct to conventional PCNSL staging, and its utility should be evaluated prospectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.